Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Biotechnology

Artiva Biotherapeutics Inc

ARTV · NASDAQ · USD · Market cap $474M · 104 employees

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.

FAIL · Does not pass the screen
3.86 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price3.86 USD at the 17 Nov 2026 close
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-17).

Current read
Distribution ?
Screened · screened 2026-11-17
  • Trend Distribution
  • Insiders insiders sold, $70,697, latest filing 2026-10-05
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price3.86 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-03Read Distribution4.19-7.9% to today ✓Markdown gives way to Distribution after a 46% slide in 6 weeks
2026-09-24Read Markdown7.83-50.7% to today ✓Accumulation gives way to Markdown after a 20% slide in 5 weeks
2026-08-22Read Accumulation9.76-60.5% to today Markdown gives way to Accumulation after a 14% rise in 7 weeks
2026-07-02Read Markdown8.54-54.8% to today ✓First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Artiva Biotherapeutics Inc holds its Distribution at $3.86. The statistical read favours the sellers, held for 13 days.

As held on the ledger · 2026-11-17
PhaseDistribution · caution
Quantitative stateThe statistical read favours the sellers, held for 13 days
Price at the screen$3.86
ValuationN/A trailing · -3.47 forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens, Shown in Full

Does not pass. Interest-bearing securities

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 8.36% Below 33% Interest-bearing debt is just 8.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 62.09% Below 33% Interest-bearing cash and securities are 62.1% of assets, above the one-third limit. Fail
Receivables 20.44% Below 49% Money owed to the company is 20.4% of assets, under the 49% limit. Pass
Revenue purity 2,131.08% Below 5% 2,131.1% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Artiva Biotherapeutics's business is fine, but its cash and interest-bearing securities are about 62% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ARTV's ethical verdict changes

Today ARTV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
23.00Street low 40.00Street average 41.00Street high 3.86Price

Third-party analyst targets. The average target sits +936% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-3.5x
EPS, trailing-3.55
EPS, forward-2.82
Profit margin0.0%currently unprofitable
Return on equity-67.9%not currently earning a positive return on equity
FCF yield-10.42%
Debt to equity0.12minimal debt: a conservative balance sheet
Current ratio8.16comfortably covers its short-term bills
Short interest, float0.04%
52-week range2.22 - 14.53
MoatNONE
Market cap$474M
Employees104

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ARTV trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-17 Distribution $4.01 -5.0% Entry 14

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-11-10 Distribution $4.22 +0.7% Entry 13

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-11-03 Distribution · changed $4.19 -30.9% Entry 12

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 30.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-10-27 Markdown $6.06 +0.0% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-10-20 Markdown $6.06 -12.7% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-10-13 Markdown $6.94 -11.4% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-10-02 Markdown $7.83 +0.0% Entry 8

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-09-24 Markdown · changed $7.83 -19.8% Entry 7

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-08-22 Accumulation · changed $9.76 +0.0% Entry 6

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36. Insiders have been net buyers over the past quarter.

2026-07-21 Markdown $9.76 +14.3% Entry 5

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 14.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 249%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it strong buy, with a mean price target of $36.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in ARTV's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · ARTV
DateInsiderTitleTypeSharesValue
2026-10-05 Horan Christopher Chief Tech Operations Officer S - Sale 10,340 $70,697
2026-10-05 Bush Jennifer COO, CLO, Compliance Officer S - Sale 8,370 $57,227
2026-10-05 Banerjee Subhashis Chief Medical Officer S - Sale 1,099 $7,514
2026-10-05 Aslan Fred CEO S - Sale 61,696 $421,828
2026-06-25 Ra Capital Management, L.P. Dir, 10% Purchase 32,876 $0

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $10.60 -31.6% · $684 -31.6%
2 months $6.81 +6.5% · $1,065 +6.5%
3 months $6.75 +7.4% · $1,074 +7.4%
6 months $3.14 +130.9% · $2,309 +130.9%
1 year $2.08 +248.6% · $3,486 +248.6%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ARTV does next, these words stay.

Artiva Biotherapeutics Inc · ARTV · Distribution · $3.86
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.